- Home
- CLST vs COEP Comparison
CLST vs COEP Comparison
Compare CLST & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLST | COEP |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 72.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLST | COEP |
|---|---|---|
| Price | $16.51 | $11.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 34.8K |
| Earning Date | 04-23-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.67 | $6.32 |
| 52 Week High | $16.98 | $21.41 |
Technical Indicators
Market Signals| Indicator | CLST | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 38.12 |
| Support Level | $16.40 | $10.98 |
| Resistance Level | $16.98 | $13.23 |
| Average True Range (ATR) | 0.09 | 1.00 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 44.00 | 17.23 |
Price Performance
Historical ComparisonAbout CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.